10:30 WELCOME AND INTRODUCTION  
DR. D. JONKER / DR. S. GILL

10:30 UPDATES FROM FINAL ANALYSES  
CO.23: A PHASE III RANDOMIZED STUDY OF BBI608 AND BEST SUPPORTIVE CARE VERSUS PLACEBO AND BEST SUPPORTIVE CARE IN PATIENTS WITH PRETREATED ADVANCED COLORECTAL CARCINOMA  
DR. D. JONKER

10:40 ACTIVE/RECENTLY CLOSED TRIALS FOR UPDATE  
CO.26: A PHASE II/III TRIAL OF DURVALUMAB AND TREMELIMUMAB AND BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH ADVANCED COLORECTAL ADENOCARCINOMA REFRACTORY TO STANDARD THERAPIES  
DR. H. KENNECKE (DR. E. CHEN)

CO.21 (CHALLENGE): A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENTS WITH EARLY STAGE COLON CANCER: A RANDOMIZED CONTROLLED TRIAL (CHALLENGE)  
DR. C. BOOTH

10:55 APPROVED TRIALS IN DEVELOPMENT  
CO.25 (FOCUS 4): MOLECULARLY STRATIFIED RCT PROGRAMME FOR SELECTION OF THERAPY IN METASTATIC CRC POST INDUCTION 1ST LINE TREATMENT  
DR. R. GOODWIN

CO.27 (IROCAS): - IRINOTECAN AND OXALIPLATIN FOR COLON CANCER IN THE ADJUVANT SETTING: MFOLFIROINOX TRIPLET CHEMOTHERAPY FOR HIGH-RISK STAGE III COLON CANCER IN ADJUVANT SETTING (IROCAS STUDY): A PHASE III RANDOMISED TRIAL  
DR. S. GILL
CANADIAN CANCER TRIALS GROUP – GI DISEASE SITE COMMITTEE

COLON
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION
VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO
DATE SATURDAY, APRIL 29th, 2017
TIME: 10:30 – 12:00
CHAIRS: DR. DEREK JONKER & DR. SHARLENE GILL

11:20  NEW CONCEPTS IN DEVELOPMENT

AGITG MONARC: A RANDOMISED PHASE 2 STUDY OF PANITUMUMAB MONOTHERAPY AND PANITUMUMAB PLUS 5 FLUOROURACIL AS FIRST LINE THERAPY FOR RAS AND BRAF WILD TYPE METASTATIC COLORECTAL CANCER  DR. D. JONKER

11:35  INTERGROUP TASK FORCE UPDATE

CR1643: PHASE II STUDY OF CIRCULATING TUMOR DNA (CTDNA) AS A PREDICTIVE MARKER FOR RESPONSE TO ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II COLON CANCER  DR. S. GILL

NRG CR1556 (COMMIT): A RANDOMIZED PHASE III STUDY OF MFOLFOX6/BEVACIZUMAB COMBINATION CHEMOTHERAPY WITH OR WITHOUT ATEZOLIZUMAB OR ATEZOLIZUMAB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) METASTATIC COLORECTAL CANCER  DR. D. JONKER

ALLIANCE A021502: RANDOMIZED PHASE III STUDY OF MFOLFOX6 X 6 MONTHS WITH OR WITHOUT ATEZOLIZUMAB X 12 MONTHS IN THE ADJUVANT TREATMENT OF PATIENTS WITH MSI-H RESECTED STAGE 3 COLON CANCER  DR. S. GILL

SWOG 1613: RANDOMIZED PHASE 2 STUDY IN HER2 AMPLIFIED MCRC AFTER FAILURE OF FIRST-LINE THERAPY  DR. S. GILL

12:00  CLOSING REMARKS